Previous 10 | Next 10 |
home / stock / dmt:cc / dmt:cc news
Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the ...
First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant -7.4 point difference between SPL026 (21.5mg) and placebo at two-weeks post-dose ...
LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it ...
LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the fi...
Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key pipeline candidates LONDON, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB...
LONDON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the fi...
LONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it wi...
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce tha...
LONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announ...
SPL028 is the Company’s injectable deuterated DMT candidate with multi-layered IP protection The Phase I study aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration of SPL028 LONDON, Oct. 31, 2022 (GLO...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET The world is facing a mental health crisis. Today, one in six individuals are likely to suffer from an episode of major depression during their lifetime that could significantly impact their relationships, work and health. Add to that the substantial negative impact t...
2024-03-27 17:08:02 ET Help for mental health sufferers Small Pharma is a neuropharmaceutical company. They specialize in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assiste...
TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire VANCOUVER, BC , Oct. 24, 2023 /CNW/ - TSX VENTURE COMPANIES MINTO METALS CORP. ("MNTO") BULLETIN TYPE: Delist BULLETIN DATE: October 24, 2023 T...